1. Tartaglia, Marco, Aoki, Yoko, Gelb, Bruce D. 2022. The molecular genetics of RASopathies: An update on novel disease genes and new disorders. In American journal of medical genetics. Part C, Seminars in medical genetics, 190, 425-439. doi:10.1002/ajmg.c.32012. https://pubmed.ncbi.nlm.nih.gov/36394128/
2. Cifuentes, Claudia, Oeste, Clara L, Fernández-Pisonero, Isabel, Bustelo, Xosé R, Alarcón, Balbino. 2024. Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer. In Molecular cancer, 23, 142. doi:10.1186/s12943-024-02054-3. https://pubmed.ncbi.nlm.nih.gov/38987766/
3. Hortal, Alejandro M, Oeste, Clara L, Cifuentes, Claudia, González, Marcos, Alarcón, Balbino. 2022. Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia. In Molecular cancer, 21, 35. doi:10.1186/s12943-022-01496-x. https://pubmed.ncbi.nlm.nih.gov/35120522/
4. Lacuna, Marta, Hortal, Alejandro M, Cifuentes, Claudia, González, Marcos, Alarcón, Balbino. 2023. Characterization of Three Somatic Mutations in the 3'UTR of RRAS2 and Their Inverse Correlation with Lymphocytosis in Chronic Lymphocytic Leukemia. In Cells, 12, . doi:10.3390/cells12232687. https://pubmed.ncbi.nlm.nih.gov/38067115/
5. Yu, Chaonan, Lyn, Nan, Li, Dongxiao, Liu, Lei, Shang, Qing. 2022. Clinical analysis of Noonan syndrome caused by RRAS2 mutations and literature review. In European journal of medical genetics, 66, 104675. doi:10.1016/j.ejmg.2022.104675. https://pubmed.ncbi.nlm.nih.gov/36460282/
6. Wang, Kejun, Peng, Kan. . RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway. In Anti-cancer drugs, 30, 933-939. doi:10.1097/CAD.0000000000000799. https://pubmed.ncbi.nlm.nih.gov/31517733/
智鼠故事 
